Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A · kind A · utility
3Cited by
31References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 6, 1998 |
| Grant date | Aug 3, 1999 |
| Priority date | — |
| Expiry date | Mar 6, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)1,4!diazepan-1-yl)-2-(aryl)butyl)b enzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.